Patents by Inventor Sergei Gryaznov

Sergei Gryaznov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10434064
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: October 8, 2019
    Assignee: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Publication number: 20190211338
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Application
    Filed: January 16, 2019
    Publication date: July 11, 2019
    Applicant: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Publication number: 20190160173
    Abstract: Oligodeoxynucleotide-based immunostimulatory Toll-Like Receptor 9 (TLR9) agonists are described. Also described are compositions comprising the TLR9 agonists, methods of making the TLR9 agonists, and methods of using the TLR9 agonists to treat immune diseases, disorders or conditions, such as viral infections or cancer.
    Type: Application
    Filed: November 2, 2018
    Publication date: May 30, 2019
    Inventors: Sergei Gryaznov, Leonid Beigelman, Theodore Yun
  • Patent number: 10208310
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: February 19, 2019
    Assignee: Exicure, Inc.
    Inventors: Christopher C. Mader, Tiffany L. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Patent number: 10196641
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: February 5, 2019
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Patent number: 10182988
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: January 22, 2019
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Publication number: 20180320184
    Abstract: Aspects of the invention relate to spherical nucleic acid-based constructs and related methods and compositions thereof.
    Type: Application
    Filed: May 15, 2018
    Publication date: November 8, 2018
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Subbarao Nallagatla, Warefta Hasan, Aaron Love, Sergei Gryaznov
  • Publication number: 20180179542
    Abstract: The present disclosure provides oligonucleotide compositions that target the covalently closed circular (ccc) DNA of hepatitis B virus (HBV). Also disclosed herein are methods for treating a subject diagnosed with, or suspected of having an HBV infection and/or an HBV-associated disorder, e.g., chronic hepatitis B infection, liver failure or cirrhosis and hepatocellular carcinoma.
    Type: Application
    Filed: November 13, 2017
    Publication date: June 28, 2018
    Applicant: Alios Biopharma, Inc.
    Inventors: Sergei Gryaznov, Megan Fitzgerald, Antitsa Dimitrova Stoycheva, Jin Hong
  • Publication number: 20180135054
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: September 14, 2017
    Publication date: May 17, 2018
    Applicant: Alios Biopharma, Inc.
    Inventors: Sergei GRYAZNOV, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong
  • Publication number: 20180119147
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Application
    Filed: October 18, 2017
    Publication date: May 3, 2018
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20180042848
    Abstract: Immunoregulatory spherical nucleic acids (irSNAs) composed of a lipid containing core and an inert Nucleic non-TLR antagonistic oligonucleotide shell are provided. Acid Shell These it-SNAs are useful for modulating an immune response.
    Type: Application
    Filed: February 18, 2016
    Publication date: February 15, 2018
    Applicant: Exicure, Inc.
    Inventors: Sergei Gryaznov, Aleksandar Filip Radovic-Moreno, Christopher C. Mader, Tiffany L. Halo, Richard Kang, Subbarao Nallagatla, Clayton Rische, Sagar Anantatatmula
  • Patent number: 9822360
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: November 21, 2017
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20170306331
    Abstract: TNF? antisense oligonucleotides are provided herein. Methods of treating TNF? diseases or Initial Screen of Phosphodiester disorders using the TNF? antisense oligonucleotides and related products are provided.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 26, 2017
    Inventors: Christopher C. Mader, Tiffany l. Halo, Sergei Gryaznov, Richard Kang, Weston Daniel
  • Publication number: 20170175121
    Abstract: Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of G-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of G-quadruplex stabilizing domains linked to the G-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as Toll-like receptors; for inhibiting DNA or RNA expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 22, 2017
    Applicant: Exicure, Inc.
    Inventor: Sergei Gryaznov
  • Publication number: 20170157048
    Abstract: Liposomal spherical nucleic acids that function as multivalent immune modulators are provided according to the invention. The liposomal spherical nucleic acids of the invention are useful prophylactic and therapeutic applications as well as research and diagnostic indications.
    Type: Application
    Filed: June 4, 2015
    Publication date: June 8, 2017
    Applicant: Exicure, Inc.
    Inventors: Aleksandar Filip Radovic-Moreno, Richard Kang, Subbarao Nallagatla, Christopher C. Mader, Sergei Gryaznov
  • Patent number: 9657296
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 23, 2017
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20170130225
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Application
    Filed: June 27, 2016
    Publication date: May 11, 2017
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20160310425
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Application
    Filed: December 3, 2014
    Publication date: October 27, 2016
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-morena, Christopher Mader
  • Patent number: 9404112
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: August 21, 2012
    Date of Patent: August 2, 2016
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Patent number: 9388416
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 12, 2016
    Inventors: Sergei Gryaznov, Krisztina Pongracz